Litcius/Paper detail

CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma

Yelei Guo, Chuan Tong, Liping Su, Wenying Zhang, Hejin Jia, Yang Liu, Qingming Yang, Zhiqiang Wu, Yao Wang, Weidong Han

2022Blood Advances30 citationsDOIOpen Access PDF

Abstract

Chimeric antigen receptor (CAR)-modified T cells have been reported to successfully treat patients with hematological malignancies. 4]

Topics & Concepts

CRISPRGenome editingLymphomaGenomeRefractory (planetary science)MedicineVirologyBiologyCancer researchGeneticsGeneInternal medicineAstrobiologyCAR-T cell therapy researchViral Infectious Diseases and Gene Expression in InsectsVirus-based gene therapy research
CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma | Litcius